Commercial formulary updates coming July 1
In July and January of each year, the Priority Health Pharmacy and Therapeutics committee makes changes to the commercial formulary to ensure our members have access to safe, effective and affordable drugs.
So far in 2019, we've added 41 new drugs to the commercial formulary. We've also reduced the tier on 17 drugs, which helps make them more affordable to our members.
On July 1, we'll have 50 changes that either remove a drug from the formulary or increase the tier. These changes impact 2,523 members. Of those members, 48% are impacted by the following five drug changes:
|Drug||Change Type||Suggested alternatives|
|Ranitidine Hcl||Remove from formulary||OTC ranitidine (brand: Zantac|
|Xulane||Tier increase||Generic contraceptives|
|Cialis||Remove from formulary||tadalafil (generic Cialis)|
|Esterified Estrogens/Methyltestosterone||Remove from formulary||Estrogen-only products, Estrogen-progestin products, selected antidepressants|
|Sumatriptan Succinate Autoinjector||Tier increase||Oral sumatriptan, naratriptan, rizatriptan, zolmitrptan|
How we're communicating to our members
Members impacted by any changes to the formulary receive a letter explaining how their drug coverage will change and what steps they can take prior to July 1, 2019. The letters also include a list of alternative medicines that may be options for them.
Our May 8 Virtual Office Advisory webinar will cover these changes. Register for the webinar so you can learn more or ask questions.